The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy
This study proposes an internally validated nomogram (PANEN-N) to accurately predict overall survival for P-NEN patients following PRRT, which could be used for patient counseling to facilitate informed and shared decision support in daily clinical practice as well as for generating new hypotheses.
Authors
- Harshad Kulkarni (ORCID: https://orcid.org/0000-0001-6164-3163)
- Thomas Langbein (ORCID: https://orcid.org/0000-0003-4258-5687)
- Richard P. Baum (ORCID: https://orcid.org/0000-0003-1723-0075)
- Sebastian Sanduleanu (ORCID: https://orcid.org/0000-0002-5961-9807)
- Aviral Singh (ORCID: https://orcid.org/0009-0003-6271-130X)
Institutions
- Spectrum Health (US)
- Fiona Stanley Hospital (AU)
- Deutsche Klinik für Diagnostik (DE)
- Zentralklinik Bad Berka (DE)
- Theranostics (New Zealand) (NZ)
- Atos Medical (DE)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-06-24
- DOI
- https://doi.org/10.3389/fendo.2025.1514792
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Health Foundation Limburg
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Center for Translational Molecular Medicine
- National Institutes of Health
- Horizon 2020 Framework Programme
- Stichting voor de Technische Wetenschappen
- Interreg
- Eurostars